查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1557333

全球癌症分析市场 – 2024 年至 2029 年预测

Global Cancer Profiling Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

癌症分析市场预计将从 2024 年的 318.16 亿美元增至 2029 年的 590.49 亿美元，复合年增长率为 13.17%。

癌症是细胞不受控制的生长，可能是致命的。环境因素是驱动细胞调节的遗传密码变化最常见的原因。细胞突变会导致细胞生长异常并影响邻近的细胞和器官。癌症或肿瘤分析是一种在肿瘤组织样本中寻找特定基因或基因突变（变化）、蛋白质或其他生物标记的诊断技术。肿瘤分析用于帮助制定治疗计划并预测癌症是否会復发或扩散到身体的其他部位。

该市场的主要成长要素是全球癌症发生率的上升以及肿瘤分析中生物标记的使用不断增加。癌症研究的增加、资助计划以及分析技术的技术开拓也推动了癌症分析市场的成长。此外，对个人化医疗和照护现场的需求不断增长预计将在整个预测期内为市场参与企业提供重大机会。

癌症分析市场驱动因素：

  • 癌症发生率的快速增加对市场成长有正面影响。

如果及早发现并给予适当的治疗，许多癌症是可以治癒的，随着全球癌症盛行率的增加，对癌症分析的需求预计也将显示出吸引力。因此，目前30-50%的癌症是可以预防的，并且可以透过对癌症患者的早期发现和适当的治疗和护理来减轻癌症的负担。

据世界卫生组织 (WHO) 称，到 2050 年，全球新增癌症病例数预计将达到 3,500 万人。这比 2022 年报告的 2,000 万新病例增加了 77%。肺癌、乳癌、摄护腺癌和大肠癌等主要癌症类型占全球盛行率的大部分，需要持续治疗。

此外，全球人口的成长进一步扩大了癌症分析的总体范围，尤其是老年人口，从而推动了市场的扩张。根据联合国资料，2024年世界人口将达到86亿，并预计在未来50至60年持续成长，到2080年代中期将达到103亿。

  • 癌症分析的积极努力预计将刺激市场成长。

为了最大限度地降低癌症相关死亡的风险并促进精准癌症医学的发展，各种筛检和生物技术公司正在着手进行癌症分析。例如，2024 年 4 月，Exact Sciences 与 Mayo Clinic 合作启动了一项遗传性癌症检测和基因组分析倡议。因此，此类倡议扩大了临床医生和研究人员的资料收集范围，以促进患者照护事业。

同样，2023 年 4 月，安捷伦科技与 Theragen Bio 签署了一份谅解备忘录，以在韩国推广精准肿瘤学。根据协议，安捷伦将提供癌症基因组分析设计和软体专业知识，以支援局部分析和治疗决策。

癌症分析市场的地理前景

  • 据估计，北美将占据重要的市场占有率。

由于加强加强癌症精准治疗，预计北美地区将显着成长并占据重要的市场占有率。为此，美国和其他主要地区正在进行各种投资和研究合作，并进行测试以选择新的治疗方法。例如，2023年2月，Exact Science Corp在美国推出了治疗方法选择测试OncoExTra(TM)。它提供次世代定序以及基于 RNA 和 DNA 的基因组测试，以帮助医生完成患者的癌症分析。

此外，美国也是癌症发生率上升的主要国家之一。例如，根据美国癌症协会预测，2024年美国癌症新增病例数预计将达到2,001万例，死亡人数将达611万例。因此，这意味着新患者增加2.6%，死亡频率增加1.7%。

灵活的美国政府法规和包括美国国立卫生研究院在内的各种组织的资助，使研究人员能够发现和开发药物、检测肿瘤并监测对癌症治疗的生物反应，并在基因生物标誌物的使用方面进行了大量投资。其他区域经济体，即加拿大，癌症死亡率也很高。据加拿大癌症协会称，到2024年，大约有247万加拿大人将被诊断出患有癌症，导致88,100人死亡。

癌症分析市场的限制因素：

  • 与样本收集相关的技术问题可能会抑制市场成长。

服务提供者最直接关心的问题之一是样本收集，然后是对这些样本的存取。这些样品受到严格的品管，必须妥善管理以避免损失。

此外，筛检计划仅对某些癌症类型有效，而不是对所有癌症类型有效。它比早期检测要困难得多，而且集中大量资源，因为它需要专门的设备和专门的人员。另一方面，高资本投资、手术成本和储存问题可能会阻碍癌症分析市场的扩张。监管标准不足、报销选择以及较低的发现与核准比率预计将为癌症分析市场带来挑战。

癌症分析 主要市场开拓

  • 2024 年 6 月，Guardant Health Inc. 宣布推出 Guardant360 TissueNext，这是一项涵盖 498 个生物标记和推荐基因的组织基因组分析测试。
  • 2024 年 3 月，Transgene、BostonGene 和 NEC 延长了 TG4​​050 I/II 期研究的合作关係。两家公司将持续进行微环境分析和肿瘤分子分析，向研究人员提供次世代定序资料，并加强开发颈癌和头癌患者的治疗性疫苗。
  • 2024年1月，QIAGEN Digital Insights推出了“QIAGEN CLC Genomics Workbench Premium”，该产品采用光速技术，支援胃癌NGS分析。该解决方案改变了全面基因组分析的游戏规则，使临床实验室能够针对体细胞应用运行高通量次世代定序仪。

癌症分析市场细分与分析如下：

依技术

  • 免疫组织化学
  • In situ Hybridization
  • 次世代定序
  • 定量聚合酵素链锁反应(qPCR)
  • 质谱分析
  • 微阵列
  • 其他的

按癌症类型

  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 黑色素瘤癌症
  • 肾癌
  • 肝癌
  • 其他的

按申请

  • 个人化医疗
  • 癌症诊断
  • 癌症研究
  • 生物标誌物搜寻
  • 治疗和监测
  • 其他的

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙
  • 其他的
  • 中东/非洲
  • 沙乌地阿拉伯
  • UAE
  • 南非
  • 其他的
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球癌症分析市场：依技术划分

  • 介绍
  • 免疫组织化学
  • 原位杂交
  • 次世代定序
  • 定量聚合酵素链锁反应(qPCR)
  • 质谱分析
  • 微阵列
  • 其他的

第六章全球癌症分析市场：依癌症类型分类

  • 介绍
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 黑色素瘤癌症
  • 肾癌
  • 肝癌
  • 其他的

第七章癌症分析的全球市场：依应用分类

  • 介绍
  • 个人化医疗
  • 肿瘤诊断
  • 癌症研究
  • 生物标记发现
  • 治疗和监测
  • 其他的

第八章全球癌症分析市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 台湾
    • 泰国
    • 印尼
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Illumina, Inc.
  • Qiagen NV
  • NeoGenomics Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Genomic Health
  • GE Healthcare
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.
  • Bio-Rad Laboratories Inc
简介目录
Product Code: KSI061612096

The global cancer profiling market is anticipated to reach US$59.049 billion in 2029 from US$31.816 billion in 2024 at a CAGR of 13.17%.

Cancer is an uncontrolled cell proliferation that has the potential to be fatal. Environmental factors are the most common source of changes in gene encoding that prompt cell regulation. Cell mutation causes aberrant cell proliferation, affecting adjacent cells and organs. Cancer or tumor profiling is a diagnostic technique that looks for specific genes or gene mutations (changes), proteins, or other biomarkers in tumor tissue samples. Tumor profiling may be used to aid treatment planning and to predict whether cancer will recur or spread to other areas of the body.

The major growth factors for this market are the rising global prevalence of cancer and the increasing use of biomarkers in tumor profiling. Increased cancer research, funding initiatives, and technical developments in profiling technologies are also driving the cancer profiling market's growth. Furthermore, the growing demand for personalized medicine and point-of-care diagnostics is projected to provide substantial possibilities for market participants throughout the forecast period.

Global Cancer Profiling Market Drivers:

  • The booming cancer prevalence has positively impacted the market growth.

Many cancers have a high chance of being cured if detected early and treated properly, and with the rising global prevalence of cancer, the demand for cancer profiling is also expected to show traction. Hence, between 30 and 50% of cancers can currently be prevented, and the cancer burden can also be reduced through early detection of cancer and appropriate treatment and care of patients who develop cancer.

According to the World Health Organization (WHO), by 2050, the global frequency of new cancer cases is estimated to reach 35 million. It will showcase a 77% growth over 20 million new cases reported in 2022. Major cancer types such as lung, breast, prostate & colorectal cancer account for a major portion of global prevalences and require constant treatment.

Additionally, the bolstering growth in the global population has further raised the overall scope of cancer profiling, especially among the older population, thereby adding more to the market expansion. As per the United Nations data, the global population stood at 8.6 billion in 2024, and for the next 50-60 years, it is expected to grow at a constant rate, thereby reaching up to 10.3 billion by the mid-2080s.

  • Favorable initiatives in cancer profiling are estimated to stimulate market growth.

To minimize the risk of cancer-related deaths and bolster the development of precision cancer medicine, various screening and biotech companies are initiating cancer profiling. For instance, in April 2024, Exact Sciences, in collaboration with Mayo Clinic, launched an initiative for hereditary cancer tests and genomic profiling. Hence, such an initiative will expand the data collection to allow clinicians and researchers to advance their careers in patient care.

Likewise, in April 2023, Agilent Technologies signed a Memorandum of Understanding (MOU) with Theragen Bio to boost precision oncology in South Korea. As per the agreement, Agilent would provide cancer genomic profiling design and software expertise for diving localized analysis and supporting treatment decisions.

Global Cancer Profiling Market Geographical Outlook

  • North America is estimated to constitute a remarkable market share.

The North American region is set to grow significantly and will account for a considerable market share fuelled by the growing efforts to bolster cancer precision treatment. It has led to various investments & research collaboration followed by new therapy selection tests in major regional economies, namely the United States. For instance, in February 2023, Exact Science Corp launched the "OncoExTra(TM)" therapy selection test in the United States. It would provide next-generation sequencing and RNA & DNA-based genomic tests that would assist doctors in completing their patient's cancer analysis.

Additionally, the United States is also one of the major nations where the frequency of cancer is on the rise. For instance, as per the American Cancer Society, for 2024, the estimated strength of new cancer cases in the United States will reach 20.01 million, with several projected deaths reaching 6.11 million. Hence, this signifies a 2.6% growth in new cases and 1.7% in death frequency.

The flexibility of US government regulations and the availability of funds from various organizations, such as the National Institute of Health, has allowed researchers to invest more in the use of biomarkers in drug discovery, drug development, tumor detection, monitoring biological response to cancer therapy, and genetic studies for the identification of cancer-predisposed candidates. Other regional economies, namely Canada, are also showcasing a higher death rate for cancer. As per the Canada Cancer Society, in 2024, approximately 2.47 million Canadians will be diagnosed with cancer, and the death count will reach 88,100.

Global Cancer Profiling Market Restraints:

  • Technical issues regarding sample collection can restrain market growth.

One of the most immediate concerns regarding service providers is sample collection, followed by access to these samples. These samples must be subjected to strict quality control and maintained properly to avoid loss.

Furthermore, screening programs are helpful for only certain types of cancer and not all. They are considerably more difficult and resource-intensive than early detection since they require specialized equipment and committed staff. On the other hand, high capital investment, procedure costs, and storage concerns will likely hinder the expansion of the cancer profiling market. Poor regulatory standards, reimbursement options, and a low discovery-to-approval ratio are expected to challenge the cancer profiling market.

Global Cancer Profiling Key Market Developments

  • In June 2024, Guardant Health Inc. launched its tissue genomic profiling test "Guardant360 TissueNext," which covers 498 biomarkers and recommended genes. This enables oncologists to target therapies and treatment strategies for patients suffering from advanced-level cancer.
  • In March 2024, Transgene, BostonGene, and NEC Corporation extended their collaboration for the Phase I/II trial of TG4050. The companies would continue performing microenvironment analysis and tumor molecular profiling, which would provide next-generation sequencing data to researchers and bolster their efforts to develop therapeutic vaccines for neck and head cancer patients.
  • In January 2024, QIAGEN Digital Insights launched its "QIAGEN CLC Genomics Workbench Premium," which features light-speed technology and supports NGS analysis for stomach cancer. The solution is a game changer for comprehensive genomic profiling and would enable clinical labs to perform high-throughput next-generation sequencing for somatic applications.

The Global Cancer Profiling market is segmented and analyzed as follows:

By Technology

  • Immunohistochemistry
  • In situ Hybridization
  • Next-Generation Sequencing
  • Quantitative Polymerase Chain Reaction (qPCR)
  • Mass Spectrometry
  • Microarrays
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma Cancer
  • Kidney Cancer
  • Liver Cancer
  • Others

By Application

  • Personalized Medicine
  • Oncological Diagnostics
  • Cancer Research
  • Biomarker Discovery
  • Treatment & Monitoring
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CANCER PROFILING MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Immunohistochemistry
  • 5.3. In situ Hybridization
  • 5.4. Next-Generation Sequencing
  • 5.5. Quantitative Polymerase Chain Reaction (qPCR)
  • 5.6. Mass Spectrometry
  • 5.7. Microarrays
  • 5.8. Others

6. GLOBAL CANCER PROFILING MARKET BY CANCER TYPE

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Lung Cancer
  • 6.4. Colorectal Cancer
  • 6.5. Prostate Cancer
  • 6.6. Melanoma Cancer
  • 6.7. Kidney Cancer
  • 6.8. Liver Cancer
  • 6.9. Others

7. GLOBAL CANCER PROFILING MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Personalized Medicine
  • 7.3. Oncological Diagnostics
  • 7.4. Cancer Research
  • 7.5. Biomarker Discovery
  • 7.6. Treatment & Monitoring
  • 7.7. Others

8. GLOBAL CANCER PROFILING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. UK
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. South Africa
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Illumina, Inc.
  • 10.2. Qiagen N.V.
  • 10.3. NeoGenomics Laboratories, Inc.
  • 10.4. F. Hoffmann-La Roche Ltd
  • 10.5. Genomic Health
  • 10.6. GE Healthcare
  • 10.7. Siemens Healthineers
  • 10.8. Thermo Fisher Scientific Inc.
  • 10.9. Hologic Inc.
  • 10.10. Bio-Rad Laboratories Inc